|
1
|
Nakamura T: Structure and function of
hepatocyte growth factor. Prog Growth Factor Res. 3:67–85. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsumoto K and Nakamura T: Hepatocyte
growth factor: Molecular structure, roles in liver regeneration and
other biological functions. Crit Rev Oncog. 3:27–54. 1992.
|
|
3
|
Pavan S, Musiani D, Torchiaro E, Migliardi
G, Gai M, Di Cunto F, Erriquez J, Olivero M and Di Renzo MF: HSP27
is required for invasion and metastasis triggered by hepatocyte
growth factor. Int J Cancer. 134:1289–1299. 2014. View Article : Google Scholar
|
|
4
|
Weidner KM, Hartmann G, Sachs M and
Birchmeier W: Properties and functions of scatter factor/hepatocyte
growth factor and its receptor c-Met. Am J Respir Cell Mol Biol.
8:229–237. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: from the perspectives of public health
problem to tumor biology. J Gastroenterol. 44(Suppl 19): 96–101.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Belghiti J and Fuks D: Liver resection and
transplantation in hepatocellular carcinoma. Liver Cancer. 1:71–82.
2012. View Article : Google Scholar
|
|
7
|
Palmer DH: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:2498author reply
2498–2499. 2008.PubMed/NCBI
|
|
8
|
Kishi Y, Hasegawa K, Sugawara Y and Kokudo
N: Hepatocellular carcinoma: Current management and future
development-improved outcomes with surgical resection. Int J
Hepatol. 2011:7281032011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ueno M, Uchiyama K, Ozawa S, Hayami S,
Shigekawa Y, Tani M and Yamaue H: Adjuvant chemolipiodolization
reduces early recurrence derived from intrahepatic metastasis of
hepatocellular carcinoma after hepatectomy. Ann Surg Oncol.
18:3624–3631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park CC, Bissell MJ and Barcellos-Hoff MH:
The influence of the microenvironment on the malignant phenotype.
Mol Med Today. 6:324–329. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu CT, Wu JR and Wu WS: The role of
endosomal signaling triggered by metastatic growth factors in tumor
progression. Cell Signal. 25:1539–1545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scagliotti GV, Novello S and von Pawel J:
The emerging role of MET/HGF inhibitors in oncology. Cancer Treat
Rev. 39:793–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Osada S, Kanematsu M, Imai H and Goshima
S: Clinical significance of serum HGF and c-Met expression in tumor
tissue for evaluation of properties and treatment of hepatocellular
carcinoma. Hepatogastroenterology. 55:544–549. 2008.PubMed/NCBI
|
|
14
|
Reik W: Stability and flexibility of
epigenetic gene regulation in mammalian development. Nature.
447:425–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robertson KD: DNA methylation and human
disease. Nat Rev Genet. 6:597–610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnson AA, Akman K, Calimport SR, Wuttke
D, Stolzing A and de Magalhães JP: The role of DNA methylation in
aging, rejuvenation and age-related disease. Rejuvenation Res.
15:483–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ting AH, Jair KW, Suzuki H, Yen RW, Baylin
SB and Schuebel KE: CpG island hypermethylation is maintained in
human colorectal cancer cells after RNAi-mediated depletion of
DNMT1. Nat Genet. 36:582–584. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patra SK, Patra A, Zhao H and Dahiya R:
DNA methyltransferase and demethylase in human prostate cancer. Mol
Carcinog. 33:163–171. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saito Y, Kanai Y, Nakagawa T, Sakamoto M,
Saito H, Ishii H and Hirohashi S: Increased protein expression of
DNA meth-yltransferase (DNMT) 1 is significantly correlated with
the malignant potential and poor prognosis of human hepatocellular
carcinomas. Int J Cancer. 105:527–532. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Girault I, Tozlu S, Lidereau R and Bièche
I: Expression analysis of DNA methyltransferases 1, 3A and 3B in
sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422.
2003.PubMed/NCBI
|
|
21
|
Etoh T, Kanai Y, Ushijima S, Nakagawa T,
Nakanishi Y, Sasako M, Kitano S and Hirohashi S: Increased DNA
methyltransferase 1 (DNMT1) protein expression correlates
significantly with poorer tumor differentiation and frequent DNA
hypermethylation of multiple CpG islands in gastric cancers. Am J
Pathol. 164:689–699. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT
and Wang YC: Alteration of DNA methyltransferases contributes to
5′CpG methylation and poor prognosis in lung cancer. Lung Cancer.
55:205–213. 2007. View Article : Google Scholar
|
|
23
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Taddei ML, Giannoni E, Comito G and
Chiarugi P: Microenvironment and tumor cell plasticity: An easy way
out. Cancer Lett. 341:80–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gaudet F, Hodgson JG, Eden A,
Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H and Jaenisch R:
Induction of tumors in mice by genomic hypomethylation. Science.
300:489–492. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Narimatsu T, Tamori A, Koh N, Kubo S,
Hirohashi K, Yano Y, Arakawa T, Otani S and Nishiguchi S: p16
promoter hyper-methylation in human hepatocellular carcinoma with
or without hepatitis virus infection. Intervirology. 47:26–31.
2004. View Article : Google Scholar
|
|
27
|
Zhang Z, Chen Y, Tang J and Xie X:
Frequent loss expression of dad2 and promotor hypermethylation in
human cancers: A meta-analysis and systematic review. Pak J Med
Sci. 30:432–437. 2014.PubMed/NCBI
|
|
28
|
Yu G, Yao W, Gumireddy K, et al:
Pseudogene PTENP1 functions as a competing endogenous RNA to
suppress clear-cell renal cell carcinoma progression. Mol Cancer
Ther. 13:3086–3097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Christoforou N, Chellappan M, Adler AF,
Kirkton RD, Wu T, Addis RC, Bursac N and Leong KW: Transcription
factors MYOCD, SRF, Mesp1 and SMARCD3 enhance the cardio-inducing
effect of GATA4, TBX5, and MEF2C during direct cellular
reprogramming. PLoS One. 8:e635772013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu C, Shao P, Bao M, et al: miR-154
inhibits prostate cancer cell proliferation by targeting CCND2.
Urol Oncol. 32:e9–e16. 2014. View Article : Google Scholar
|
|
31
|
Ogunwobi OO, Puszyk W, Dong HJ and Liu C:
Epigenetic upregulation of HGF and c-Met drives metastasis in
hepatocellular carcinoma. PLoS One. 8:e637652013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kivelä R, Bry M, Robciuc MR, Räsänen M,
Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A,
Mäyränpää MI, et al: VEGF-B-induced vascular growth leads to
metabolic reprogramming and ischemia resistance in the heart. EMBO
Mol Med. 6:307–321. 2014.PubMed/NCBI
|
|
33
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suárez-Causado A, Caballero-Díaz D,
Bertrán E, et al: HGF/c-Met signaling promotes liver progenitor
cell migration and invasion by an epithelial-mesenchymal
transition-independent, phosphatidyl inositol-3 kinase-dependent
pathway in an in vitro model. Biochim Biophys Acta. S0167-4889(15):
00163–9. 2015.
|
|
35
|
Lordick F: Targeting the HGF/MET pathway
in gastric cancer. Lancet Oncol. 15:914–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tischoff I and Tannapfe A: DNA methylation
in hepatocellular carcinoma. World J Gastroenterol. 14:1741–1748.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Massagué J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar
|
|
39
|
Dong C, Wu Y, Yao J, Wang Y, Yu Y,
Rychahou PG, Evers BM and Zhou BP: G9a interacts with Snail and is
critical for Snail-mediated E-cadherin repression in human breast
cancer. J Clin Invest. 122:1469–1486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY,
Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al: Bmi1 is
essential in Twist1-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ,
Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, et al: EZH2 supports
nasopharyngeal carcinoma cell aggressiveness by forming a
co-repressor complex with HDAC1/HDAC2 and Snail to inhibit
E-cadherin. Oncogene. 31:583–594. 2012.
|
|
42
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
43
|
Wang D, Chang PS, Wang Z, Sutherland L,
Richardson JA, Small E, Krieg PA and Olson EN: Activation of
cardiac gene expression by myocardin, a transcriptional cofactor
for serum response factor. Cell. 105:851–862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Failli V, Rogard M, Mattei MG, Vernier P
and Rétaux S: Lhx9 and Lhx9alpha LIM-homeodomain factors: Genomic
structure, expression patterns, chromosomal localization and
phylogenetic analysis. Genomics. 64:307–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vladimirova V, Mikeska T, Waha A,
Soerensen N, Xu J, Reynolds PC and Pietsch T: Aberrant methylation
and reduced expression of LHX9 in malignant gliomas of childhood.
Neoplasia. 11:700–711. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lai CP, Bechberger JF and Naus CC:
Pannexin2 as a novel growth regulator in C6 glioma cells. Oncogene.
28:4402–4408. 2009. View Article : Google Scholar : PubMed/NCBI
|
